NeoGenomics Reports Full-Year 2025 Results with Increased Loss, Significant Impairments, and Key Patent Litigation Win

summarizeSummary

NeoGenomics filed its annual 10-K, confirming double-digit revenue growth for 2025 but also reporting a substantial increase in net loss and significant asset impairments, while highlighting the favorable resolution of a major patent infringement lawsuit.

check_boxKey Events

• Full-Year 2025 Financials

  Revenue increased 10.1% to $727.3 million, and Adjusted EBITDA grew 9.5% to $43.4 million. However, net loss widened significantly to $(108.0) million from $(78.7) million in 2024.

• Strategic Asset Impairments

  The company recorded $15.9 million in impairment charges related to the sale of Trapelo Health, LLC assets and an additional $11.4 million impairment on InVisionFirst-Lung intangible assets, totaling $27.3 million.

• Patent Litigation Victory

  NeoGenomics successfully resolved a patent infringement lawsuit with Natera, Inc., with the district court granting summary judgment in favor of NeoGenomics and Natera withdrawing its appeal.

• Liquidity Update

  Cash and cash equivalents decreased to $159.6 million at year-end 2025 from $367.0 million in 2024, partly due to the repayment of $201.3 million in 2025 Convertible Notes.

auto_awesomeAnalysis

NeoGenomics' annual 10-K filing provides comprehensive audited financial results for 2025, detailing a year of mixed performance. While the company achieved double-digit revenue and Adjusted EBITDA growth, it also reported a substantial increase in net loss and significant asset impairments. A major positive development is the favorable resolution of a patent infringement lawsuit, removing a notable legal overhang. Investors should consider the company's continued revenue growth against the backdrop of widening losses, asset write-downs, and a decrease in cash reserves, while acknowledging the de-risking from the legal victory.